Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date

Apixaban, a direct orally active anticoagulant (selective, direct factor Xa inhibitor) is approved for (primary) prevention of venous thromboembolism (VTE) in patients undergoing elective total-hip or total-knee arthroplasty, for acute treatment/prevention of recurrent events in patients with VTE, a...

Descripción completa

Detalles Bibliográficos
Autor principal: Trkulja, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762581/
https://www.ncbi.nlm.nih.gov/pubmed/26937206
http://dx.doi.org/10.2147/DHPS.S74410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762581/
https://www.ncbi.nlm.nih.gov/pubmed/26937206
http://dx.doi.org/10.2147/DHPS.S74410

Ejemplares similares